PRT811 / Prelude Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  PRT811 / Prelude Therap, Lenvima (lenvatinib) / Eisai, Merck (MSD), PRT543 / Prelude Therap
    PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands (Grand Ballroom GHIJ) -  Mar 5, 2024 - Abstract #AHNSCOSM2024AHNS_COSM_59;    
    Identifying PRMT5 as a putative candidate, we next determined the applicability of PRMT5 inhibitors (PRT543 and PRT811) using ACC cell lines, organoids, and patient derived xenograft (PDX) models. Our study underscores the role of PRMT5 in ACC and supports PRMT5 blockade as a promising strategy for treating this rare disease.
  • ||||||||||  PRT811 / Prelude Therap
    Trial completion date, Trial primary completion date, Metastases:  A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas (clinicaltrials.gov) -  Nov 30, 2022   
    P1,  N=145, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Feb 2023 | Trial primary completion date: Oct 2022 --> Feb 2023
  • ||||||||||  Review, Journal, IO biomarker:  Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. (Pubmed Central) -  Aug 30, 2022   
    Highly significant is a durable complete response in isocitrate dehydrogenase 1-mutated glioblastoma multiforme with PRT811...Further studies are warranted, and there are clinical trials to come whose data will be telling of the efficacy of PRMT5 inhibitors in both hematologic and solid malignancies. The aim of this study is to compile available results of PRMT5 inhibitors in oncology clinical trials.
  • ||||||||||  PRT811 / Prelude Therap
    Characterization of factors affecting sensitivity and resistance to PRMT5 inhibition in glioblastoma (Section 24) -  Mar 9, 2022 - Abstract #AACR2022AACR_4039;    
    Our results demonstrate pharmacological PRMT5 inhibition induced SDMA reduction and late apoptosis in genetically and epigenetically heterogeneous patient-derived GSC lines and that mutant p53 lines are less sensitive to PRMT5 inhibition. Additional studies related to splicing defects upon PRMT5 inhibition are ongoing and will be presented at the meeting.
  • ||||||||||  PRT811 / Prelude Therap
    Enrollment change, Trial primary completion date, Metastases:  A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas (clinicaltrials.gov) -  Nov 2, 2021   
    P1,  N=145, Recruiting, 
    Additional studies related to splicing defects upon PRMT5 inhibition are ongoing and will be presented at the meeting. N=75 --> 145 | Trial primary completion date: Oct 2021 --> Oct 2022
  • ||||||||||  temozolomide / Generic mfg.
    Discovery of PRT811, a potent, selective, and orally bioavailable brain penetrant PRMT5 Inhibitor for the treatment of brain tumors (Virtual Meeting II: E-Posters) -  May 16, 2020 - Abstract #AACRII2020AACR-II_4045;    
    P1
    Moreover, in a U-87 MG subcutaneous xenograft model in nude rats, once daily oral dosing of PRT811 at 20 and 30 mg/kg resulted in 91% and 100% tumor growth inhibition, respectively. PRT811 and related analogues are being studied across a panel of primary human and murine brain tumors ex vivo, and in vivo in primary orthotopic models of CNS lymphoma, a rare and aggressive subset of non-Hodgkins lymphomas.PRT811 is currently under evaluation in a Phase I clinical trial in patients with advanced solid tumors, gliomas, and myelofibrosis (NCT04089449).
  • ||||||||||  PRT811 / Prelude Therap
    Enrollment open, Metastases:  A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas (clinicaltrials.gov) -  Nov 10, 2019   
    P1,  N=125, Recruiting, 
    PRT811 and related analogues are being studied across a panel of primary human and murine brain tumors ex vivo, and in vivo in primary orthotopic models of CNS lymphoma, a rare and aggressive subset of non-Hodgkins lymphomas.PRT811 is currently under evaluation in a Phase I clinical trial in patients with advanced solid tumors, gliomas, and myelofibrosis (NCT04089449). Not yet recruiting --> Recruiting